Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors

Metabolic reprogramming via an engineered PGC-1α improves human chimeric antigen receptor T-cell therapy against solid tumors

Background Cellular immunotherapies for cancer represent a means by which a patient’s immune system can be augmented with high numbers of tumor-specific T cells. Chimeric antigen receptor (CAR) therapy involves genetic engineering to ‘redirect’ peripheral T cells to tumor targets, showing remarkable...

Full description

Bibliographic Details
Main Authors: Benjamin Boyerinas, Greg M Delgoffe, Yupeng Wang, Alok Kumar, Ashley V Menk, Konstantinos Lontos, Yiyang Wang, Jason Lohmueller, Supriya K Joshi, Andrew T Frisch, McLane J Watson, Rachel Cumberland, Esteban Carrizosa
Format: Article
Language:English
Published: BMJ Publishing Group 2023-03-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/3/e006522.full

Internet

https://jitc.bmj.com/content/11/3/e006522.full

Similar Items